Evidence map›Paper›PMID 34070953›Full record

ArticleCancers2021

2-[

Aida Sabaté-Llobera, Judit Mestres-Martí, Gabriel Reynés-Llompart, Laura Lladó, Kristel Mils, Teresa Serrano, Montserrat Cortés-Romera, Esther Bertran, Isabel Fabregat, Emilio Ramos

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Comparison ofCancer science · 2025
    Article
  5. The potential ofAbdominal radiology (New York) · 2024
    Article
  6. Head-to-head comparison ofCancer imaging : the official publication of the International Cancer Imaging Society · 2023
    Article
  7. Article
  8. Tumor metabolism derived fromQuantitative imaging in medicine and surgery · 2023
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Aida Sabaté-LloberaPET Unit, Department of Nuclear Medicine-IDI, University Hospital of Bellvitge, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.ORCID 0000-0002-5580-3391
Judit Mestres-MartíPET Unit, Department of Nuclear Medicine-IDI, University Hospital of Bellvitge, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
Gabriel Reynés-LlompartPET Unit, Department of Nuclear Medicine-IDI, University Hospital of Bellvitge, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
Laura LladóBellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain.ORCID 0000-0002-3717-3306
Kristel MilsBellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain.
Teresa SerranoBellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain.
Montserrat Cortés-RomeraPET Unit, Department of Nuclear Medicine-IDI, University Hospital of Bellvitge, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
Esther BertranOncology Program, Centro de Investigación Biomédica en Red, Enfermedades Hepáticas y Digestivas (CIBEREHD), National Biomedical Research Institute on Liver and Gastrointestinal Diseases, Instituto de Salud Carlos III, 28029 Madrid, Spain.
Isabel FabregatBellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain.ORCID 0000-0003-0136-8440
Emilio RamosBellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain.ORCID 0000-0002-2688-0101
Bellvitge University Hospital · ESInstituto de Salud Carlos III · ES

Funding

Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación (cofounded by FEDER funds/European REgional Development Fund - a way to build Europe) #RTI2018-094079Centres de Recerca de CatalunyaIDIBELL FoundationInstituto de Salud Carlos III
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) generally presents a low avidity for 2-deoxy-2-[

Indexed as

2-[18F]FDGcellular differentiation.hepatocellular carcinomalean body massliver resectionmicrovascular invasionPET/CTstandardized uptake value

Identifiers

PMID34070953
PMCPMC8196959
OpenAlexW3164955487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.